E-viri
-
Biotech Week, 08/2005Newsletter
Significant accomplishments during the quarter included the following: 184% increase in Q2 FY 2005 revenues vs. Q2 FY2004; 50% sequential increase in Q2 FY 2005 revenues vs. Q1 FY2005; gross profit increased 183% from Q1 FY2005, resulting in a near doubling of gross profit margins to 43.8%; and 65% increase in testing volume in Q2 FY 2005 vs. Q1 FY 2005; 30% of cases ordered more than one test per case vs. 24% of cases in Q1 FY2005.
